Bardelli et al.[29] reported that patients with metastatic disease that are “quadruple negative” in the KRAS-BRAF-PIK3CA-PTEN gene set have the highest probability of response to anti-EGFR therapies. Here, PTEN is linked to metastatic neoplasm.